Five Prime Therapeutics Announces Upcoming Presentations at the 2014 American Association for Cancer Research Meeting


SOUTH SAN FRANCISCO, Calif., March 27, 2014 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that data related to FP-1039 (GSK3052230), an FGF ligand trap in a global, multi-arm Phase 1b study, and FPA144, a monoclonal antibody against the FGF receptor 2b, will be presented at the American Association for Cancer Research (AACR) Annual Meeting. The meeting will be held April 5-9, 2014 in San Diego, CA.

The following four posters will be presented:

Abstract Number 2845: "Expression of FGFR2b in gastric cancer as measured by immunohistochemistry with a highly specific monoclonal antibody," Amit M. Deshpande, et al. The poster will be presented Monday, April 7 from 1:00 P.M. to 5:00 P.M. in Hall A-E, Poster Section 37 on Poster Board Number 26. 

Abstract Number LB-236: "Preclinical efficacy of targeting FGF autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230," M. Phillip De Young, et al. The poster will be presented Tuesday, April 8 from 8:00 A.M. to 12:00 P.M. in Hall A-E, Poster Section 42. 

Abstract Number 5446: "FPA144: A therapeutic antibody for treating patients with gastric cancers bearing FGFR2 gene amplification," Abigael T. Gemo, et al. The poster will be presented Wednesday, April 9 from 8:00 A.M. to 12:00 P.M. in Hall A-E, Poster Section 30 on Poster Board Number 22. 

Abstract Number 5449: "FP-1039/GSK3052230, an FGF ligand trap, enhances VEGF antagonist therapy in preclinical models of RCC and HCC," David Bellovin, et al. The poster will be presented Wednesday, April 9 from 8:00 A.M. to 12:00 P.M. in Hall A-E, Poster Section 30 on Poster Board Number 25. 

About Five Prime

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases. Five Prime has leveraged its comprehensive library of human extracellular proteins and its proprietary high-throughput screening technologies to produce new targets for protein therapeutics to be advanced by partners or in the company's internal pipeline.

FP-1039 (GSK3052230) is a fibroblast growth factor (FGF) ligand trap being developed in collaboration with GlaxoSmithKline to treat multiple solid tumors. A global, multi-arm Phase 1b study of FP-1039 in combination with standard chemotherapy in FGFR1 gene-amplified squamous non-small cell lung cancer (NSCLC) and mesothelioma is underway. FPA008, a monoclonal antibody that inhibits colony stimulating factor-1 receptor (CSF1R) activation and is being developed to treat rheumatoid arthritis, is in a Phase 1 trial currently enrolling. FPA144 is a monoclonal antibody that blocks signaling through fibroblast growth factor receptor 2b (FGFR2b) and is glyco-engineered for enhanced antibody-dependent cytotoxicity. For more information please see: www.fiveprime.com.



            

Contact Data